Podoplanin is overexpressed in head and neck squamous cell carcinomas (HNSCC) and is associated with poor clinical outcome

被引：0
|
作者：
Yuan, Ping [1 ]
Temam, Stephane [1 ]
Ei-Naggar, Adel [1 ]
Zhou, Xian [1 ]
Lee, Jack [1 ]
Mao, Li [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4476
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immunohistochemical detection of cell cycle regulatory proteins.: Poor prognostic significance in patients with advanced head and neck squamous cell carcinomas (HNSCC)
    Kunz, C
    Bosch, FX
    Klein-Kühne, W
    Nollert, J
    Rudat, V
    Conradt, C
    Dietz, A
    HNO, 2003, 51 (10) : 800 - 805
  • [22] Bax/Bak requirement in (-)-gossypol-induced cell death in head and neck squamous cell carcinomas (HNSCC)
    Brenner, John C.
    Wolter, Keith G.
    Bauer, Joshua A.
    Verhaegen, Monique
    Wang, Shaomeng
    Soengas, Maria
    Bradford, Carol R.
    Carey, Thomas E.
    CANCER RESEARCH, 2006, 66 (08)
  • [23] Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
    Shutong Liu
    Bo Ren
    Hang Gao
    Suchan Liao
    Ying-Xian Zhai
    Shirong Li
    Xue-Jin Su
    Ping Jin
    David Stroncek
    Zhixiang Xu
    Qinghua Zeng
    Yulin Li
    Journal of Translational Medicine, 15
  • [24] Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck
    Villavicencio, Michelle
    Granados-Garcia, Martin
    Vilajosana, Esther
    Dominguez-Cherit, Judith
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (06) : 602 - 609
  • [25] Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
    Liu, Shutong
    Ren, Bo
    Gao, Hang
    Liao, Suchan
    Zhai, Ying-Xian
    Li, Shirong
    Su, Xue-Jin
    Jin, Ping
    Stroncek, David
    Xu, Zhixiang
    Zeng, Qinghua
    Li, Yulin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [26] Clinical trial design limitations in head and neck squamous cell carcinomas
    Yun, Hwan Jung
    Bogaerts, Jan
    Awada, Ahmad
    Lacombe, Denis
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (03) : 210 - 215
  • [27] Clinical relevance of tumour markers in head and neck squamous cell carcinomas
    Stieber, P
    Wollenberg, B
    Schmitt, UM
    vonJan, N
    Hofmann, K
    FatehMoghadam, A
    TUMORDIAGNOSTIK & THERAPIE, 1996, 17 (04) : 116 - 121
  • [28] Methylene tetrahydrofolate dehydrogenase 2 (MTHFD2) is overexpressed in head and neck squamous cell carcinoma (HNSCC) and correlated with patient's poor prognosis
    Sun, Biqiang
    He, Zhijun
    Liu, Gan
    Fu, Xiao
    Chen, Zhiyong
    Li, Guoli
    PTERIDINES, 2021, 32 (01) : 98 - 105
  • [29] Cetuximab in squamous cell head and neck carcinomas
    Gebbia, V.
    Giuliani, F.
    Valori, V. M.
    Agueli, R.
    Coiucci, G.
    Maiello, E.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 7
  • [30] Expression and prognostic significance of a panel of tissue hypoxia markers in head and neck squamous cell carcinomas (HNSCC)
    Le, Q.
    Kong, C.
    Lavori, P. W.
    Erler, J.
    Huang, X.
    Chen, Y.
    Cao, H.
    Denko, N.
    Giaccia, A.
    Koong, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S186 - S187
12345